Corporate Governance

Chair’s Introduction

Incanthera’s Board and management team possess a broad range of commercial, scientific and public company experience.

The Board comprises individuals who have all held long and distinguished position within the healthcare industry.

Our CEO, Dr Simon Ward’s scientific and educational background, along with commercial experience provides the perfect platform to oversee his vision to transform the method and quality of technologies from laboratory to patient, that is the heart of Incanthera’s business.

My own experience in 40 years of healthcare and corporate roles combined, has provided the opportunity of Chairmanships and team building, alongside all aspects of commercial and industry activity, and I am delighted to be part of the team here at Incanthera.

We are fortunate to have had the long term support of Caroline Murray, as Non-Executive Director, whose large Pharma and cross- section of company experience, provides an invaluable sounding board of perception and wise counsel.

We are delighted to recently appoint John Howes, as Non-Executive Director and Senior Independent Director. John’s first class corporate and City experience of over 40 years in UK equity capital markets, brings the Board a solid support in his institutional relationship expertise and corporate guidance as we propel further in our commercial ambitions.

Our Key Senior Management team is diverse and skilled, providing every aspect we require to not only progress, but flourish. Their individual qualities have shown resilience, determination and the experience to fulfil our ambitions.

Laura Brogden, CFO, ensures our financial accounting, management and compliance obligations are fulfilled and met with ample time and poise.

Suzanne Brocks, Head of Communications and Company Secretary, oversees City, company and public facing communications, and oversees all shareholder information and compliance, ensuring both internally, and to the public, that we are delivering our message and maximising our opportunities, in line with regulations and governance.

These full spectrum qualities, ensure industry and commercial ambitions are met and opportunities and evolution are at the forefront of our strategic drive year after year and I can say with confidence that the team at Incanthera is the right one to deliver our own growth and commercialisation goals into future rewards to shareholders.

Tim McCarthy

Tim has 40 years’ international senior level business experience in the Healthcare, Biotech and Technology sectors.

He is also CEO of ImmuPharma PLC an AIM quoted specialist drug discovery and development company and Chairman of 4basebio PLC, an AIM quoted company developing next generation gene therapy technologies and solutions.

Tim is a former CEO and Finance Director of a number of public and private companies, including Alizyme plc and Peptide Therapeutics Group plc. He has also co-founded a number of healthcare and biotechnology companies. A Fellow of the Association of Chartered Certified Accountants, he also has an MBA from Cranfield School of Management.

Dr Simon Ward
Chief Executive Officer

Simon is a co-founder of Incanthera and has more than 30 years’ senior experience in academia and business.

He was a founder and CEO of Molecular SkinCare Limited, a pioneer and developer of novel dermatology products for the prevention and management of skin diseases. As CSO of York Pharma plc, he was responsible for bringing innovative dermatology product through to market. Simon also served as chairman of South Yorkshire Bioscience Enterprise Network (SYBEN) and deputy chairman of Medipex, a healthcare innovation hub for NHS organisations across industry and academia internationally.

Simon graduated from the University of London’s School of Pharmacy (UK) with a Joint Honours Degree in Pharmacology and Toxicology and was awarded a DPhil in the Department of Human Anatomy, Oxford University under a Glaxo Group Research Studentship.

For the lead development programme, Sol, the Company is working closely with two key individuals:

Professor Mike Cork

Working at the Sheffield Children’s Hospital and Sheffield Teaching Hospitals, Mike is a world-recognised opinion leader in disorders of the skin barrier and inventor of dermatological products. He runs a dedicated clinical research facility focused upon the response of normal and diseased skin to topical product.

Dr Kevin Hammond

Dr. Hammond has over 30 years’ experience working with some of the world’s leading Pharmaceutical, FMCG and Healthcare companies, where he has held responsibilities in directing new product innovation, partnering, licensing, and technology acquisition, for companies such as Reckitt Benckiser, Unilever, PZ Cussons, CB Fleet (US) and GSK. His experience includes operations in Europe, Latin America, North America, South East Asia and Central Asia.

In 2010, Dr. Hammond set up his own consultancy aimed at advising and working with SMEs and University spin-out companies seeking to commercialise their technologies in the Pharmaceutical, Healthcare and FMCG markets. Since this time, he has secured significant returns for clients through facilitating ‘entry’ into potential customer companies, partnering contracts, technology sales, and licensing and royalty agreements, including deals with companies such as P&G, GSK and Coty.